Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SPIN4 | Q56A73 | 1/20 | 0.32 |
| ▸ | SPIN3 | Q5JUX0 | 1/20 | 0.32 |
| ▸ | SPIN2B | Q9BPZ2 | 1/20 | 0.32 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475087 | 1.00 | BRAF (0.33) | BRAFQPCTHTR1DHTR1BHTR2A | |
| SCHEMBL1656702 | 0.91 | AURKA (0.39) | BRAFMAPTLCKABL1BCR | |
| SCHEMBL29475034 | 0.91 | AURKA (0.39) | BRAFMAPTLCKABL1BCR | |
| SCHEMBL29475091 | 0.91 | MAPT (0.34) | QPCTHTR1DHTR1BHTR2AATR | |
| SCHEMBL1655754 | 0.91 | MAPT (0.34) | QPCTHTR1DHTR1BHTR2AATR | |
| SCHEMBL16892879 | 0.90 | QPCT (0.32) | QPCTSPIN4SPIN3SPIN2BSPIN1 | |
| SCHEMBL1656050 | 0.88 | ATR (0.33) | QPCTHTR1DHTR1BHTR2AATR | |
| SCHEMBL29475026 | 0.88 | ATR (0.33) | QPCTHTR1DHTR1BHTR2AATR | |
| SCHEMBL1656717 | 0.85 | MET (0.42) | ATRMAPTABL1BCR | |
| SCHEMBL1656091 | 0.85 | MCHR1 (0.36) | QPCTHTR1DHTR1BHTR2AATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843743-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | Bayer AS (NO) | 2021-07-07 | — | — | EP | claimed |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | claimed |
| WO-2020164997-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | claimed |
| WO-2020043617-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2020-03-05 | — | — | WO | claimed |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-22 | — | — | US | claimed |
| EP-2983669-B1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS | Bayer Pharma AG (DE) | 2018-10-24 | — | — | EP | claimed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | claimed |
| US-20180042929-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-15 | — | — | US | claimed |
| EP-3268005-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-17 | — | — | EP | claimed |
| US-20160303136-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | claimed |
| US-20150141420-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-21 | — | — | US | claimed |
| US-20140243295-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-28 | — | — | US | claimed |
| EP-2694069-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2014-02-12 | — | — | EP | claimed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | claimed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| WO-2012136549-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | claimed |
| US-20110251191-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | claimed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | claimed |
| EP-2168582-A1 | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| EP-2168583-A1 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | BRAF 205/4885QPCT 1680/4885HTR1D 2341/4885 |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | BRAF 198/4885QPCT 1474/4885HTR1D 4809/4885 |
| US-20150141420-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | MCL1, BCL9, BCL3 | BRAF 1765/4885QPCT 440/4885HTR1D 4195/4885 |
| US-20140243295-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BRCA1, PIK3CA, PTEN | BRAF 188/4885QPCT 2001/4885HTR1D 3590/4885 |
| US-20180042929-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | PIK3R4, PIK3R5, PIK3C2B | BRAF 183/4885QPCT 1887/4885HTR1D 2668/4885 |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BCL9L, BCL9, MALT1 | BRAF 30/4885QPCT 1688/4885HTR1D 4089/4885 |
| US-20160303136-A1 | COMBINATION OF PI3K-INHIBITORS | PIK3CA, AKT3, AKT2 | BRAF 53/4885QPCT 1697/4885HTR1D 4556/4885 |
| US-20110251191-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | MCL1, BCL9, BCL3 | BRAF 1765/4885QPCT 440/4885HTR1D 4195/4885 |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | PIK3CA, PIK3CD, PIK3CB | BRAF 205/4885QPCT 1680/4885HTR1D 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.